Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-parallel study of Huangqi San pellets in diabetic kidney disease with qi deficiency syndrome
CTR20202484Phase 2Active
- Sponsor
- Consun Pharmaceutical Group
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of huangqi san in diabetic glomerulosclerosis, sponsored by Consun Pharmaceutical Group. Started Mar 2021; status: active.
02
Drugs
huangqi san
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on CTR20202484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202484.